Sample Request

Global Sickle Cell Anemia Therapeutics Market Size, Status and Forecast 2020-2026

SELECT LICENSE:

Published on 07/29/2020| Code: QYR56111D| Category: Healthcare & Life Sciences| Total Pages: 97

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

The classification of Sickle Cell Anemia Therapeutics includes Blood Transfusion, Pharmacotherapy and Bone Marrow Transplant, and the proportion of Blood Transfusion in 2017 is about 45%, and the proportion of Bone Marrow Transplant in 2017 is about 35%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Sickle Cell Anemia Therapeutics market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Sickle Cell Anemia Therapeutics industry.

Based on our recent survey, we have several different scenarios about the Sickle Cell Anemia Therapeutics YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 2700.6 million in 2019. The market size of Sickle Cell Anemia Therapeutics will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Sickle Cell Anemia Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Sickle Cell Anemia Therapeutics market in terms of revenue.

Players, stakeholders, and other participants in the global Sickle Cell Anemia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Sickle Cell Anemia Therapeutics market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Sickle Cell Anemia Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Sickle Cell Anemia Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Sickle Cell Anemia Therapeutics market.

The following players are covered in this report:

BioMarin

Bluebird Bio

DeuteRx

Emmaus Medical

Gamida Cell

Global Blood Therapeutics

GlycoMimetics

Modus Therapeutics

Pfizer

Sancilio Pharmaceuticals

Sangamo Biosciences

Sickle Cell Anemia Therapeutics Breakdown Data by Type

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Sickle Cell Anemia Therapeutics Breakdown Data by Application

Hospitals

Clinics

Others

1 Report Overview

    1.1 Study Scope

    1.2 Key Market Segments

    1.3 Players Covered: Ranking by Sickle Cell Anemia Therapeutics Revenue

    1.4 Market Analysis by Type

        1.4.1 Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type: 2020 VS 2026

        1.4.2 Blood Transfusion

        1.4.3 Pharmacotherapy

        1.4.4 Bone Marrow Transplant

    1.5 Market by Application

        1.5.1 Global Sickle Cell Anemia Therapeutics Market Share by Application: 2020 VS 2026

        1.5.2 Hospitals

        1.5.3 Clinics

        1.5.4 Others

    1.6 Coronavirus Disease 2019 (Covid-19): Sickle Cell Anemia Therapeutics Industry Impact

        1.6.1 How the Covid-19 is Affecting the Sickle Cell Anemia Therapeutics Industry

            1.6.1.1 Sickle Cell Anemia Therapeutics Business Impact Assessment - Covid-19

            1.6.1.2 Supply Chain Challenges

            1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products

        1.6.2 Market Trends and Sickle Cell Anemia Therapeutics Potential Opportunities in the COVID-19 Landscape

        1.6.3 Measures / Proposal against Covid-19

            1.6.3.1 Government Measures to Combat Covid-19 Impact

            1.6.3.2 Proposal for Sickle Cell Anemia Therapeutics Players to Combat Covid-19 Impact

    1.7 Study Objectives

    1.8 Years Considered

2 Global Growth Trends by Regions

    2.1 Sickle Cell Anemia Therapeutics Market Perspective (2015-2026)

    2.2 Sickle Cell Anemia Therapeutics Growth Trends by Regions

        2.2.1 Sickle Cell Anemia Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026

        2.2.2 Sickle Cell Anemia Therapeutics Historic Market Share by Regions (2015-2020)

        2.2.3 Sickle Cell Anemia Therapeutics Forecasted Market Size by Regions (2021-2026)

    2.3 Industry Trends and Growth Strategy

        2.3.1 Market Top Trends

        2.3.2 Market Drivers

        2.3.3 Market Challenges

        2.3.4 Porter’s Five Forces Analysis

        2.3.5 Sickle Cell Anemia Therapeutics Market Growth Strategy

        2.3.6 Primary Interviews with Key Sickle Cell Anemia Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

    3.1 Global Top Sickle Cell Anemia Therapeutics Players by Market Size

        3.1.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue (2015-2020)

        3.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2015-2020)

        3.1.3 Global Sickle Cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

    3.2 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio

        3.2.1 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)

        3.2.2 Global Top 10 and Top 5 Companies by Sickle Cell Anemia Therapeutics Revenue in 2019

    3.3 Sickle Cell Anemia Therapeutics Key Players Head office and Area Served

    3.4 Key Players Sickle Cell Anemia Therapeutics Product Solution and Service

    3.5 Date of Enter into Sickle Cell Anemia Therapeutics Market

    3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

    4.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Type (2015-2020)

    4.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2021-2026)

5 Sickle Cell Anemia Therapeutics Breakdown Data by Application (2015-2026)

    5.1 Global Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

    5.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

    6.1 North America Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    6.2 Sickle Cell Anemia Therapeutics Key Players in North America (2019-2020)

    6.3 North America Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    6.4 North America Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

7 Europe

    7.1 Europe Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    7.2 Sickle Cell Anemia Therapeutics Key Players in Europe (2019-2020)

    7.3 Europe Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    7.4 Europe Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

8 China

    8.1 China Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    8.2 Sickle Cell Anemia Therapeutics Key Players in China (2019-2020)

    8.3 China Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    8.4 China Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

9 Japan

    9.1 Japan Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    9.2 Sickle Cell Anemia Therapeutics Key Players in Japan (2019-2020)

    9.3 Japan Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    9.4 Japan Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

    10.1 Southeast Asia Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    10.2 Sickle Cell Anemia Therapeutics Key Players in Southeast Asia (2019-2020)

    10.3 Southeast Asia Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    10.4 Southeast Asia Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

11 India

    11.1 India Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    11.2 Sickle Cell Anemia Therapeutics Key Players in India (2019-2020)

    11.3 India Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    11.4 India Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

12 Central & South America

    12.1 Central & South America Sickle Cell Anemia Therapeutics Market Size (2015-2020)

    12.2 Sickle Cell Anemia Therapeutics Key Players in Central & South America (2019-2020)

    12.3 Central & South America Sickle Cell Anemia Therapeutics Market Size by Type (2015-2020)

    12.4 Central & South America Sickle Cell Anemia Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

    13.1 BioMarin

        13.1.1 BioMarin Company Details

        13.1.2 BioMarin Business Overview and Its Total Revenue

        13.1.3 BioMarin Sickle Cell Anemia Therapeutics Introduction

        13.1.4 BioMarin Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020))

        13.1.5 BioMarin Recent Development

    13.2 Bluebird Bio

        13.2.1 Bluebird Bio Company Details

        13.2.2 Bluebird Bio Business Overview and Its Total Revenue

        13.2.3 Bluebird Bio Sickle Cell Anemia Therapeutics Introduction

        13.2.4 Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.2.5 Bluebird Bio Recent Development

    13.3 DeuteRx

        13.3.1 DeuteRx Company Details

        13.3.2 DeuteRx Business Overview and Its Total Revenue

        13.3.3 DeuteRx Sickle Cell Anemia Therapeutics Introduction

        13.3.4 DeuteRx Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.3.5 DeuteRx Recent Development

    13.4 Emmaus Medical

        13.4.1 Emmaus Medical Company Details

        13.4.2 Emmaus Medical Business Overview and Its Total Revenue

        13.4.3 Emmaus Medical Sickle Cell Anemia Therapeutics Introduction

        13.4.4 Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.4.5 Emmaus Medical Recent Development

    13.5 Gamida Cell

        13.5.1 Gamida Cell Company Details

        13.5.2 Gamida Cell Business Overview and Its Total Revenue

        13.5.3 Gamida Cell Sickle Cell Anemia Therapeutics Introduction

        13.5.4 Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.5.5 Gamida Cell Recent Development

    13.6 Global Blood Therapeutics

        13.6.1 Global Blood Therapeutics Company Details

        13.6.2 Global Blood Therapeutics Business Overview and Its Total Revenue

        13.6.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Introduction

        13.6.4 Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.6.5 Global Blood Therapeutics Recent Development

    13.7 GlycoMimetics

        13.7.1 GlycoMimetics Company Details

        13.7.2 GlycoMimetics Business Overview and Its Total Revenue

        13.7.3 GlycoMimetics Sickle Cell Anemia Therapeutics Introduction

        13.7.4 GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.7.5 GlycoMimetics Recent Development

    13.8 Modus Therapeutics

        13.8.1 Modus Therapeutics Company Details

        13.8.2 Modus Therapeutics Business Overview and Its Total Revenue

        13.8.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Introduction

        13.8.4 Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.8.5 Modus Therapeutics Recent Development

    13.9 Pfizer

        13.9.1 Pfizer Company Details

        13.9.2 Pfizer Business Overview and Its Total Revenue

        13.9.3 Pfizer Sickle Cell Anemia Therapeutics Introduction

        13.9.4 Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.9.5 Pfizer Recent Development

    13.10 Sancilio Pharmaceuticals

        13.10.1 Sancilio Pharmaceuticals Company Details

        13.10.2 Sancilio Pharmaceuticals Business Overview and Its Total Revenue

        13.10.3 Sancilio Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction

        13.10.4 Sancilio Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        13.10.5 Sancilio Pharmaceuticals Recent Development

    13.11 Sangamo Biosciences

        10.11.1 Sangamo Biosciences Company Details

        10.11.2 Sangamo Biosciences Business Overview and Its Total Revenue

        10.11.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Introduction

        10.11.4 Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2015-2020)

        10.11.5 Sangamo Biosciences Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

    15.1 Research Methodology

        15.1.1 Methodology/Research Approach

        15.1.2 Data Source

    15.2 Disclaimer

    15.3 Author Details

Our Clients

BIC
Suntory Holdings
Continental AG
Ernst Klett
felix
IF Logo
ITC logo
jc
KB
KKR
LR
LSC
Mizuno corporation
Prospect
SRG
Sumitomo
Taichin logo
The Cleanest Way
Meat & Livestock Australia Limited
LEK
IFFCO
STTS
Laundry Capital LLC
Chippenhook Corporation
SAB

Need Help?

Please fill form below:

Contact Us

99 WALL STREET #2124 NEW YORK, NY 10005